The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
T-Cell Immunotherapy-Global Market Insights and Sales Trends 2025
Synopsis
CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach Cancer, Lung Cancer, Colorectal Cancer and Esophagus Cancer, are propelling T-Cell Immunotherapy market. CAR-T, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the TCR segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for T-Cell Immunotherapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global T-Cell Immunotherapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global T-Cell Immunotherapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, T-Cell Immunotherapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of T-Cell Immunotherapy covered in this report include Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Kite Pharma, Novartis, Takara Bio and Unum Therapeutics, etc.
The global T-Cell Immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Kite Pharma
Novartis
Takara Bio
Unum Therapeutics
Global T-Cell Immunotherapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global T-Cell Immunotherapy market, Segment by Type:
CAR-T
TCR
TIL Therapies
Global T-Cell Immunotherapy market, by Application
Stomach Cancer
Lung Cancer
Colorectal Cancer
Esophagus Cancer
Pancreatic Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of T-Cell Immunotherapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach Cancer, Lung Cancer, Colorectal Cancer and Esophagus Cancer, are propelling T-Cell Immunotherapy market. CAR-T, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the TCR segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for T-Cell Immunotherapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global T-Cell Immunotherapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global T-Cell Immunotherapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, T-Cell Immunotherapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of T-Cell Immunotherapy covered in this report include Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Kite Pharma, Novartis, Takara Bio and Unum Therapeutics, etc.
The global T-Cell Immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Kite Pharma
Novartis
Takara Bio
Unum Therapeutics
Global T-Cell Immunotherapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global T-Cell Immunotherapy market, Segment by Type:
CAR-T
TCR
TIL Therapies
Global T-Cell Immunotherapy market, by Application
Stomach Cancer
Lung Cancer
Colorectal Cancer
Esophagus Cancer
Pancreatic Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of T-Cell Immunotherapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of T-Cell Immunotherapy
1.1 T-Cell Immunotherapy Market Overview
1.1.1 T-Cell Immunotherapy Product Scope
1.1.2 T-Cell Immunotherapy Market Status and Outlook
1.2 Global T-Cell Immunotherapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global T-Cell Immunotherapy Market Size by Region (2018-2029)
1.4 Global T-Cell Immunotherapy Historic Market Size by Region (2018-2023)
1.5 Global T-Cell Immunotherapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, T-Cell Immunotherapy Market Size (2018-2029)
1.6.1 North America T-Cell Immunotherapy Market Size (2018-2029)
1.6.2 Europe T-Cell Immunotherapy Market Size (2018-2029)
1.6.3 Asia-Pacific T-Cell Immunotherapy Market Size (2018-2029)
1.6.4 Latin America T-Cell Immunotherapy Market Size (2018-2029)
1.6.5 Middle East & Africa T-Cell Immunotherapy Market Size (2018-2029)
2 T-Cell Immunotherapy Market by Type
2.1 Introduction
2.1.1 CAR-T
2.1.2 TCR
2.1.3 TIL Therapies
2.2 Global T-Cell Immunotherapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global T-Cell Immunotherapy Historic Market Size by Type (2018-2023)
2.2.2 Global T-Cell Immunotherapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America T-Cell Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe T-Cell Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific T-Cell Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America T-Cell Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa T-Cell Immunotherapy Revenue Breakdown by Type (2018-2029)
3 T-Cell Immunotherapy Market Overview by Application
3.1 Introduction
3.1.1 Stomach Cancer
3.1.2 Lung Cancer
3.1.3 Colorectal Cancer
3.1.4 Esophagus Cancer
3.1.5 Pancreatic Cancer
3.1.6 Others
3.2 Global T-Cell Immunotherapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global T-Cell Immunotherapy Historic Market Size by Application (2018-2023)
3.2.2 Global T-Cell Immunotherapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America T-Cell Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe T-Cell Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific T-Cell Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America T-Cell Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa T-Cell Immunotherapy Revenue Breakdown by Application (2018-2029)
4 T-Cell Immunotherapy Competition Analysis by Players
4.1 Global T-Cell Immunotherapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in T-Cell Immunotherapy as of 2022)
4.3 Date of Key Players Enter into T-Cell Immunotherapy Market
4.4 Global Top Players T-Cell Immunotherapy Headquarters and Area Served
4.5 Key Players T-Cell Immunotherapy Product Solution and Service
4.6 Competitive Status
4.6.1 T-Cell Immunotherapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Adaptimmune
5.1.1 Adaptimmune Profile
5.1.2 Adaptimmune Main Business
5.1.3 Adaptimmune T-Cell Immunotherapy Products, Services and Solutions
5.1.4 Adaptimmune T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.1.5 Adaptimmune Recent Developments
5.2 Altor Bioscience Corporation
5.2.1 Altor Bioscience Corporation Profile
5.2.2 Altor Bioscience Corporation Main Business
5.2.3 Altor Bioscience Corporation T-Cell Immunotherapy Products, Services and Solutions
5.2.4 Altor Bioscience Corporation T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.2.5 Altor Bioscience Corporation Recent Developments
5.3 Cellectis
5.3.1 Cellectis Profile
5.3.2 Cellectis Main Business
5.3.3 Cellectis T-Cell Immunotherapy Products, Services and Solutions
5.3.4 Cellectis T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.3.5 Juno Therapeutics Recent Developments
5.4 Juno Therapeutics
5.4.1 Juno Therapeutics Profile
5.4.2 Juno Therapeutics Main Business
5.4.3 Juno Therapeutics T-Cell Immunotherapy Products, Services and Solutions
5.4.4 Juno Therapeutics T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.4.5 Juno Therapeutics Recent Developments
5.5 Kite Pharma
5.5.1 Kite Pharma Profile
5.5.2 Kite Pharma Main Business
5.5.3 Kite Pharma T-Cell Immunotherapy Products, Services and Solutions
5.5.4 Kite Pharma T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.5.5 Kite Pharma Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis T-Cell Immunotherapy Products, Services and Solutions
5.6.4 Novartis T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Takara Bio
5.7.1 Takara Bio Profile
5.7.2 Takara Bio Main Business
5.7.3 Takara Bio T-Cell Immunotherapy Products, Services and Solutions
5.7.4 Takara Bio T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.7.5 Takara Bio Recent Developments
5.8 Unum Therapeutics
5.8.1 Unum Therapeutics Profile
5.8.2 Unum Therapeutics Main Business
5.8.3 Unum Therapeutics T-Cell Immunotherapy Products, Services and Solutions
5.8.4 Unum Therapeutics T-Cell Immunotherapy Revenue (US$ Million) & (2018-2023)
5.8.5 Unum Therapeutics Recent Developments
6 North America
6.1 North America T-Cell Immunotherapy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe T-Cell Immunotherapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific T-Cell Immunotherapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America T-Cell Immunotherapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa T-Cell Immunotherapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 T-Cell Immunotherapy Market Dynamics
11.1 T-Cell Immunotherapy Industry Trends
11.2 T-Cell Immunotherapy Market Drivers
11.3 T-Cell Immunotherapy Market Challenges
11.4 T-Cell Immunotherapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
